Inve India ▾

Zim Laboratories share price & results

Zim Laboratories Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Nagpur-based pharmaceutical maker specialising in novel drug-delivery technologies — oral thin films, new innovative products and complex generic formulations, plus a nutraceuticals business.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue93.1 ₹ crore+30.3% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin2.6 %−3.5 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit-3.9 ₹ crore—Quarterly, as filedQuarter to Jun 2026Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown.
Return on equity1.35 %−3.1 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin3.00 %+2.8 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)7.55 %−4.6 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

3 of 5 judged targets kept · 11 open · verdicts reflect calls analysed to Q1 FY27.

Zim Laboratories Limited management guidance track record on Inve: 16 targets tracked across analysed earnings calls (3 achieved, 2 missed, 11 open).

TargetOriginal wordingSaidLatest callVerdict
EU-GMP Reinspection / Audit Completionwithin the next 6 months
Call transcript, Q1 FY26 · 12 Aug 2025		Q1 FY26Q1 FY27:Promise previously achieved in Q4 FY26.
Call transcript, Q1 FY27 · 7 Aug 2026		Achieved
NIP and OTF contribution to total turnover30% to 40% going forward
Call transcript, Q4 FY25 · 22 May 2025		Q4 FY25Q1 FY27:Dropped to 18% for the quarter, described as a 'normalized' level. Still significantly below the 30-40% target.
Call transcript, Q1 FY27 · 7 Aug 2026		Missed
EBITDA Margin15% - 17% by FY26-27
Call transcript, Q4 FY25 · 22 May 2025		Q4 FY25Q1 FY27:Dropped to 3.7% for the quarter. Management now guides for mid-teens in FY28, contingent on EU-GMP, pushing out the timeline.
Call transcript, Q1 FY27 · 7 Aug 2026		At Risk

Source: Inve Guidance Tracker for Zim Laboratories Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

2 of Zim Laboratories Limited's 16 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 13 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹133.82 +5.63% · +₹7.13

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +94.3% 1Y

₹60₹80₹100₹120₹140₹160Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 17 Nov 2025Q3 FY26 — 13 Feb 2026Q4 FY26 — 20 May 2026Q1 FY27 — 7 Aug 2026

1Y: ₹68.88 on 24 Oct 2025 → ₹133.82. High ₹152.63 (12 Oct 2026), low ₹60.26 (30 Mar 2026).

Previous close
₹126.69
Market cap
₹691 Cr
52-week range
₹60.26 – ₹152.63
One year
+93.27%
Price to earnings (TTM to Jun 2026)
186.76×
Return on equity (TTM to Jun 2026)
1.35%

Overview

Symbol
NSE:ZIMLAB
Exchange
NSE
Currency
INR

What Zim Laboratories Limited does

Based on the company's own presentations, annual report and earnings calls.

Zim Laboratories develops, manufactures and supplies differentiated and complex generic pharmaceutical products in oral solid dosage forms, built on proprietary, non-infringing novel drug delivery technologies (NDDS). Its Pharmaceuticals division makes Pre-Formulation Intermediates, Finished Formulations, Oral Thin Films (OTF) and New Innovative Products (NIP) sold into regulated, pharmerging and RoW markets, while its Nutraceuticals division supplies vitamins, healthcare and dietary supplements. Manufacturing is carried out across three facilities in Nagpur, Maharashtra, supported by an in-house R&D team that develops the company's proprietary technology platforms.

Segments

  • Pharmaceuticals
  • Nutraceuticals
Manufacturing facilities
3 in Nagpur — Solid Oral Dosage (General) 1,00,000 sq.ft, Solid Oral Dosage (Cephalosporin) 16,000 sq.ft, Oral Thin Film 6,300 sq.ft
Production utilisation rate
65%
Marketing Authorisations received (cumulative)
34 (NIP 5, OTF 25, FF 4)
Regulatory filings completed (cumulative)
57 (NIP 14, OTF 29, FF 14)
Proprietary technology platforms
4 non-infringing platforms
Therapy segments covered
7
Founded 1989Headquarters Nagpur, Maharashtra, India Company website

How the price took the results

close before → close after

Q1 FY27
−2.8%
7 Aug
Q4 FY26
−1.5%
20 May
Q3 FY26
−4.8%
13 Feb
Q2 FY26
−1.9%
17 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Zim Laboratories Limited

Free account: one company. Everything above stays public.

Write why you follow Zim Laboratories Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Zim Laboratories Limited

Guides on how to read this kind of business and the numbers that matter.